Skip to main content
. 2020 Nov 18;7(11):200909. doi: 10.1098/rsos.200909

Table 3.

A comparison of published seroprevalence studies with our estimated true cumulative infection rates: the study, the country where the samples were collected, the region where the samples were collected, the dates when the samples were collected, the reported rate of seroprevalence (best estimate and 95% confidence interval), and the estimated true cumulative infection rate according to this study (median and 95% confidence interval).

study country location dates seroprevalence (%) this study (%)
Havers et al. [6] USA Western Washington State 23 March–1 April 2020 1.1 (0.7–1.9) 1.40 (0.86–2.36)
New York City metro area 23 March–1 April 2020 6.9 (5.0–8.9) 1.40 (0.86–2.36)
Louisiana 1–8 April 2020 5.8 (3.9–8.2) 2.07 (1.41–3.66)
South Florida 6–10 April 2020 1.9 (1.0–3.2) 2.35 (1.61–4.14)
Philadelphia metro area 13–25 April 2020 3.2 (1.7–5.2) 3.09 (2.15–5.44)
Missouri 20–26 April 2020 2.7 (1.7–3.9) 3.34 (2.32–5.88)
Utah 20 April–3 May 2020 2.2 (1.2–3.4) 3.52 (2.45–6.19)
San Francisco Bay area 23–27 April 2020 1.0 (0.3–2.4) 3.45 (2.40–6.07)
Connecticut 26 April–3 May 2020 4.9 (3.6–6.5) 3.68 (2.56–6.47)
Minneapolis–St Paul–St Cloud metro area 30 April–12 May 2020 2.4 (1.0–4.5) 3.97 (2.76–6.97)
Bendavid et al. [2] USA Santa Clara County, California 3–4 April 2020 2.8 (1.3–4.7)a 1.99 (1.35–3.52)
Pollán et al. [30] Spain nationwide 27 April–11 May 2020 6.2 (5.8–6.6)b 7.68 (5.35–13.48)
Hicks et al. [7] Australia nationwide May–June 2020 0.28 (0.00–0.71) 0.06 (0.04–0.10)c

aWeighted by the authors for the population demographics of Santa Clara County.

bEither point-of-care test or immunoassay positive.

cStatistics are calculated for the period 1 May–30 June 2020.